IL18 and metastatic melanoma: Our new results suggest that adoptive transfer of IL-12 and IL-18 preactivated NK cells simultaneously treated with exogenous low dose of IL-2 may have an important place in immunotherapy of metastatic melanoma patients especially those patients belonging to M1a and M1b categories that have better survival outcome and prognosis.